BBNX Chief Commercial Officer Mark Hopman Sells $13K of Stock
Mark Hopman trimmed a small position in Beta Bionics shares via a pre-arranged trading plan.
Reviewed by automated data checks against the source filing. How we make and check alerts
Mark Hopman, Chief Commercial Officer at Beta Bionics, Inc. ($BBNX), sold 775 shares at an average price of $17.35, worth about $13,446.25, on October 14, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $BBNX is down 3.1% to date (from the $16.87 close on Oct 14, 2026).
BBNX
Beta Bionics, Inc.
Key Points
- Beta Bionics chief commercial officer Mark Hopman sold 775 shares at $17.35 apiece on October 14, 2026.
- After the trade, Mark Hopman holds 55,334 $BBNX shares, down 1.38% from before the trade.
- The planned sale was executed under a Rule 10b5-1 trading plan and totaled $13,446.25.
- The stock traded around $16.45 on October 16, 2026, down about 2.5% since the transaction date.
Get $BBNX trade alerts by text
We text you when insiders, Congress or big funds trade $BBNX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Beta Bionics, Inc. alert may contain errors. Disclosures
Beta Bionics, Inc. BBNX Chief Commercial Officer Mark Hopman sold 775 shares of the medical device maker on October 14, 2026, according to a Form 4 filed with the Securities and Exchange Commission.
Inside Mark Hopman's Beta Bionics Trade
The planned sale took place at a price of $17.35 per share, resulting in a total value of $13,446.25. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. On the day of the trade, Beta Bionics stock closed at $16.87. This follows several earlier transactions by Hopman, including a sale of 370 shares on October 1, 2026, at $18.96 per share and another sale on September 16, 2026.
Other Institutional Activity in Beta Bionics
Eventide Asset Management LLC grew its holdings by 307,987 shares, ending with 6,253,673 shares worth about $102,247,555. Soleus Capital Management, L.P. grew its holdings by 39,191 shares, ending with 4,393,714 shares worth about $71,837,225. Morgan Stanley grew its holdings by 39,316 shares, ending with 4,266,822 shares worth about $69,762,541. Sands Capital Alternatives, LLC held its position steady with 3,708,043 shares worth about $60,626,504. Blackrock Inc. grew its holdings by 301,442 shares, ending with 3,340,171 shares worth about $54,611,797.
Beta Bionics, Inc. Stock Down 24.8%
Shares recently traded around $16.45 as of October 16, 2026, putting the price about 2.5% below the closing level of $16.87 on the day of the insider trade.
Recent Earnings
Beta Bionics reported trailing-twelve-month revenue of $119,013,000 and basic earnings per share of -$1.60. The company's next earnings update is scheduled for October 27, 2026.
Insider Buying and Selling at Beta Bionics, Inc.
Insiders have been active in recent weeks. Mike Mensinger sold 2,650 shares on September 16, 2026, at $22.00 per share for a total of $58,300. Christy Jones sold 6,430 shares on September 22, 2026, at $23.00 per share for a total of $147,890.
Analysts Set New Price Targets
On September 15, 2026, B of A Securities maintained a Neutral rating and raised its target from $18.00 to $20.00. On the same day, Truist Securities reiterated a Buy rating and raised its target from $22.00 to $23.00. Wells Fargo initiated coverage on September 23, 2026, with an Overweight rating and a $28.00 price target. Truist Securities maintained a Buy rating on September 24, 2026, and raised its target to $28.00. Jefferies initiated coverage on October 12, 2026, with a Buy rating and a $30.00 price target.
About Beta Bionics
Beta Bionics, Inc. designs and commercializes medical devices to help people with diabetes manage insulin delivery. Its flagship product is the iLet Bionic Pancreas, an automated insulin delivery system used by adults and children.
Bottom Line
Investors will watch for the company's financial update on October 27, 2026, to gauge ongoing commercial progress for its bionic pancreas technology.
Related Filing Alerts
Source: Mark Hopman's Form 4 filing on $BBNX (Oct 14, 2026). Read the original filing: Form 4 filing on SEC EDGAR. Written by software, not financial advice. How we make alerts